- Home
- HSHP vs TRDA Comparison
HSHP vs TRDA Comparison
Compare HSHP & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSHP
- TRDA
- Stock Information
- Founded
- HSHP 2021
- TRDA 2016
- Country
- HSHP Bermuda
- TRDA United States
- Employees
- HSHP N/A
- TRDA N/A
- Industry
- HSHP
- TRDA Biotechnology: Pharmaceutical Preparations
- Sector
- HSHP
- TRDA Health Care
- Exchange
- HSHP Nasdaq
- TRDA Nasdaq
- Market Cap
- HSHP 268.6M
- TRDA 264.4M
- IPO Year
- HSHP 2023
- TRDA 2021
- Fundamental
- Price
- HSHP $7.74
- TRDA $6.95
- Analyst Decision
- HSHP
- TRDA Strong Buy
- Analyst Count
- HSHP 0
- TRDA 2
- Target Price
- HSHP N/A
- TRDA $24.50
- AVG Volume (30 Days)
- HSHP 134.9K
- TRDA 209.6K
- Earning Date
- HSHP 11-06-2025
- TRDA 11-06-2025
- Dividend Yield
- HSHP 6.22%
- TRDA N/A
- EPS Growth
- HSHP N/A
- TRDA N/A
- EPS
- HSHP 0.11
- TRDA N/A
- Revenue
- HSHP $119,380,000.00
- TRDA $61,520,000.00
- Revenue This Year
- HSHP $7.01
- TRDA N/A
- Revenue Next Year
- HSHP $20.02
- TRDA N/A
- P/E Ratio
- HSHP $68.91
- TRDA N/A
- Revenue Growth
- HSHP 6.29
- TRDA N/A
- 52 Week Low
- HSHP $4.29
- TRDA $4.93
- 52 Week High
- HSHP $8.95
- TRDA $21.79
- Technical
- Relative Strength Index (RSI)
- HSHP 46.28
- TRDA 58.77
- Support Level
- HSHP $7.37
- TRDA $6.09
- Resistance Level
- HSHP $7.85
- TRDA $7.10
- Average True Range (ATR)
- HSHP 0.17
- TRDA 0.48
- MACD
- HSHP -0.02
- TRDA -0.01
- Stochastic Oscillator
- HSHP 52.70
- TRDA 59.52
About HSHP Himalaya Shipping Ltd.
Himalaya Shipping Ltd is an independent dry bulk company that focuses on owning and operating its Newcastlemax dry bulk carriers.
About TRDA Entrada Therapeutics Inc.
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.